UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in AdaptHealth Corp. (NASDAQ:AHCO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of AdaptHealth Corp. (NASDAQ:AHCO) by 7.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 162,470 shares of the company’s stock after buying an additional 11,757 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in AdaptHealth were worth $1,825,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Canada Pension Plan Investment Board bought a new position in AdaptHealth during the 2nd quarter valued at approximately $58,000. Blue Trust Inc. purchased a new position in shares of AdaptHealth during the second quarter valued at approximately $85,000. Innealta Capital LLC bought a new position in shares of AdaptHealth during the second quarter valued at approximately $101,000. Quest Partners LLC lifted its stake in AdaptHealth by 11,522.7% in the second quarter. Quest Partners LLC now owns 10,228 shares of the company’s stock worth $102,000 after acquiring an additional 10,140 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in AdaptHealth in the second quarter valued at $113,000. 82.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other AdaptHealth news, COO Shaw Rietkerk sold 25,000 shares of AdaptHealth stock in a transaction on Friday, September 20th. The shares were sold at an average price of $11.24, for a total value of $281,000.00. Following the transaction, the chief operating officer now directly owns 212,611 shares of the company’s stock, valued at approximately $2,389,747.64. The trade was a 10.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.43% of the company’s stock.

AdaptHealth Stock Performance

NASDAQ AHCO opened at $9.55 on Monday. The company has a market cap of $1.29 billion, a P/E ratio of -5.79, a P/E/G ratio of 1.36 and a beta of 1.10. The business’s 50 day moving average price is $10.14 and its 200-day moving average price is $10.45. AdaptHealth Corp. has a fifty-two week low of $6.43 and a fifty-two week high of $11.90. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.02). The business had revenue of $805.90 million for the quarter, compared to analysts’ expectations of $809.32 million. AdaptHealth had a negative net margin of 6.57% and a positive return on equity of 9.62%. AdaptHealth’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.19 EPS. Sell-side analysts predict that AdaptHealth Corp. will post 0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on AHCO. Royal Bank of Canada decreased their price objective on shares of AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, November 19th. Truist Financial decreased their price target on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Robert W. Baird cut their price objective on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group reduced their target price on AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, UBS Group lowered their target price on AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, AdaptHealth presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.